27-Mar-2026
Newsfile (Fri, 27-Mar 6:14 PM ET)
Globe Newswire (Fri, 27-Mar 6:09 PM ET)
Globe Newswire (Fri, 27-Mar 1:20 PM ET)
Globe Newswire (Fri, 27-Mar 10:54 AM ET)
Newsfile (Thu, 26-Mar 6:33 PM ET)
Globe Newswire (Wed, 25-Mar 6:12 PM ET)
PRNewswire (Wed, 25-Mar 4:57 PM ET)
PRNewswire (Wed, 25-Mar 9:01 AM ET)
Globe Newswire (Tue, 24-Mar 11:19 AM ET)
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Inovio Pharmaceuticals trades on the NASDAQ stock market under the symbol INO.
As of March 27, 2026, INO stock price climbed to $1.61 with 1,466,849 million shares trading.
INO has a beta of 1.29, meaning it tends to be more sensitive to market movements. INO has a correlation of 0.07 to the broad based SPY ETF.
INO has a market cap of $111.24 million. This is considered a Micro Cap stock.
Last quarter Inovio Pharmaceuticals reported $0 in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-20,000 and exceeded earnings estimates by $.09.
In the last 3 years, INO traded as high as $14.75 and as low as $1.30.
The top ETF exchange traded funds that INO belongs to (by Net Assets): VTI, VXF, IWC.
INO has underperformed the market in the last year with a return of -8.5%, while the SPY ETF gained +13.1%. In the last 3 month period, INO fell short of the market, returning -29.7%, while SPY returned -7.9%. However, in the most recent 2 weeks INO has outperformed the stock market by returning -3.0%, while SPY returned -4.0%.
INO support price is $1.50 and resistance is $1.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INO shares will trade within this expected range on the day.
